Flotate receptor-targeted liposomes with encapsulated anti-sarcosine antibodies for attenuation of prostate tumors

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216305%3A26620%2F16%3APU122191" target="_blank" >RIV/00216305:26620/16:PU122191 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Flotate receptor-targeted liposomes with encapsulated anti-sarcosine antibodies for attenuation of prostate tumors
Original language description
Prostate cancer is the most occurring malignancy in men from USA or Western Europe with 29% of men of 30 to 40 years of age and 64% of men of 60 to 70 years of age suffering from prostate cancer [1]. One of the delineated oncometabolites in prostate cancer is the amino acid sarcosine (N-methylglycine) that plays a substantial role in progression of prostate cancer[2]. In this work, anti-sarcosine antibodies were employed for attenuation of prostate tumours in xenograft mice. The antibodies were modified with CdTe quantum dots for the detection of their intracellular delivery. Free antibodies are unable to enter intracellular space, so to enable internalization of these antibodies in the tumour intracellular space needed for subsequent neutralization of sarcosine, the antibodies were encapsulated in liposomes with loading efficiency of 69.2%. To increase the shuttling efficiency of antibodies-loaded liposomes, their surface was modified with folate, enabling entering of tumour cells via clathrin-mediat
Czech name
—
Czech description
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)